FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020105240> ?p ?o ?g. }

• W2020105240 endingPage "463" @default.
• W2020105240 startingPage "456" @default.
• W2020105240 abstract "Thalidomide and its analogs are effective agents in the treatment of multiple myeloma. Since gelatinases (matrix metalloproteinases-2 and -9) play a crucial role in tumor progression, we explored the effect of thalidomide on gelatinase production by malignant B lymphoid cell lines.We investigated the effect of therapeutic doses of thalidomide on integrin-mediated production of gelatinases by malignant B lymphoid cell lines by gelatin zymography, western-blot, reverse transcriptase polymerase chain reaction and invasive capacity through Matrigel-coated Boyden chambers. We also explored the effect of thalidomide on the activation status of the main signaling pathways involved in this process.Thalidomide strongly inhibited gelatinase production by B-cell lines and primary myeloma cells in response to fibronectin, the most efficient gelatinase inducer identified in lymphoid cells. Thalidomide disrupted integrin-mediated signaling pathways involved in gelatinase induction and release, such as Src and MAP-kinase ERK activation, resulting in decreased cell motility and invasiveness. Unexpectedly, treatment with thalidomide elicited an increase in fibronectin-induced Akt phosphorylation through phosphoinositide 3-kinase-independent pathways since thalidomide decreased fibronectin-induced phosphoinositide 3-kinase phosphorylation and reversed the inhibition of Akt phosphorylation achieved by the phosphoinositide 3-kinase inhibitors wortmannin and LY294002.Disruption of integrin-mediated signaling may be an important mechanism through which thalidomide and its analogs impair tumor cell interactions with the microenvironment. The unexpected effects of thalidomide on Akt activation indicate the need for further studies to elucidate whether the interference with Akt downstream effects would synergize with the anti-tumor activity of thalidomide." @default.
• W2020105240 created "2016-06-24" @default.
• W2020105240 creator A5001546418 @default.
• W2020105240 creator A5023487394 @default.
• W2020105240 creator A5028498042 @default.
• W2020105240 creator A5031837957 @default.
• W2020105240 creator A5044095970 @default.
• W2020105240 creator A5053832306 @default.
• W2020105240 creator A5059764745 @default.
• W2020105240 creator A5073663285 @default.
• W2020105240 creator A5083966917 @default.
• W2020105240 date "2009-10-08" @default.
• W2020105240 modified "2023-09-25" @default.
• W2020105240 title "Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways" @default.
• W2020105240 cites W1552949608 @default.
• W2020105240 cites W1564633285 @default.
• W2020105240 cites W1597238753 @default.
• W2020105240 cites W1656339735 @default.
• W2020105240 cites W169514863 @default.
• W2020105240 cites W1777794242 @default.
• W2020105240 cites W1779659318 @default.
• W2020105240 cites W1853544818 @default.
• W2020105240 cites W1947748380 @default.
• W2020105240 cites W1966133006 @default.
• W2020105240 cites W1978591675 @default.
• W2020105240 cites W1984461699 @default.
• W2020105240 cites W1985147506 @default.
• W2020105240 cites W1998214332 @default.
• W2020105240 cites W2002062371 @default.
• W2020105240 cites W2008299686 @default.
• W2020105240 cites W2010012376 @default.
• W2020105240 cites W2010552629 @default.
• W2020105240 cites W2013647024 @default.
• W2020105240 cites W2026445018 @default.
• W2020105240 cites W2036691369 @default.
• W2020105240 cites W2036988959 @default.
• W2020105240 cites W2059084316 @default.
• W2020105240 cites W2059552745 @default.
• W2020105240 cites W2074780626 @default.
• W2020105240 cites W2076627331 @default.
• W2020105240 cites W2101307567 @default.
• W2020105240 cites W2104028456 @default.
• W2020105240 cites W2104897208 @default.
• W2020105240 cites W2107252423 @default.
• W2020105240 cites W2128049766 @default.
• W2020105240 cites W2136373453 @default.
• W2020105240 cites W2142042013 @default.
• W2020105240 cites W2142712146 @default.
• W2020105240 cites W2151768635 @default.
• W2020105240 cites W2158008984 @default.
• W2020105240 cites W2159679541 @default.
• W2020105240 cites W2170411142 @default.
• W2020105240 cites W2171663131 @default.
• W2020105240 cites W2335120005 @default.
• W2020105240 doi "https://doi.org/10.3324/haematol.2009.006395" @default.
• W2020105240 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2833076" @default.
• W2020105240 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19815837" @default.
• W2020105240 hasPublicationYear "2009" @default.
• W2020105240 type Work @default.
• W2020105240 sameAs 2020105240 @default.
• W2020105240 citedByCount "13" @default.
• W2020105240 countsByYear W20201052402013 @default.
• W2020105240 countsByYear W20201052402014 @default.
• W2020105240 countsByYear W20201052402015 @default.
• W2020105240 countsByYear W20201052402016 @default.
• W2020105240 countsByYear W20201052402018 @default.
• W2020105240 countsByYear W20201052402020 @default.
• W2020105240 countsByYear W20201052402021 @default.
• W2020105240 countsByYear W20201052402022 @default.
• W2020105240 crossrefType "journal-article" @default.
• W2020105240 hasAuthorship W2020105240A5001546418 @default.
• W2020105240 hasAuthorship W2020105240A5023487394 @default.
• W2020105240 hasAuthorship W2020105240A5028498042 @default.
• W2020105240 hasAuthorship W2020105240A5031837957 @default.
• W2020105240 hasAuthorship W2020105240A5044095970 @default.
• W2020105240 hasAuthorship W2020105240A5053832306 @default.
• W2020105240 hasAuthorship W2020105240A5059764745 @default.
• W2020105240 hasAuthorship W2020105240A5073663285 @default.
• W2020105240 hasAuthorship W2020105240A5083966917 @default.
• W2020105240 hasBestOaLocation W20201052401 @default.
• W2020105240 hasConcept C109523444 @default.
• W2020105240 hasConcept C1491633281 @default.
• W2020105240 hasConcept C185592680 @default.
• W2020105240 hasConcept C189165786 @default.
• W2020105240 hasConcept C195687474 @default.
• W2020105240 hasConcept C203014093 @default.
• W2020105240 hasConcept C2776223131 @default.
• W2020105240 hasConcept C2776232661 @default.
• W2020105240 hasConcept C2776364478 @default.
• W2020105240 hasConcept C2776912716 @default.
• W2020105240 hasConcept C2778308172 @default.
• W2020105240 hasConcept C2779609412 @default.
• W2020105240 hasConcept C502942594 @default.
• W2020105240 hasConcept C55493867 @default.
• W2020105240 hasConcept C62478195 @default.
• W2020105240 hasConcept C75217442 @default.
• W2020105240 hasConcept C86554907 @default.
• W2020105240 hasConcept C86803240 @default.

• next